Plantcaps® capsule

Lonza Engine™ offers state-of-the-art equipment designed to address the needs of customers throughout the entire drug development process including:  ​  ​

·         Liquid-filled hard capsules filling and sealing equipment: support fo...

The Capsugel® capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.

DRcaps® capsules are innovative HPMC capsules that can help protect dietary supplement ingredients from stomach acidity without the cost and complexity of adding acid-resistant properties during manufacturing. DRcaps® capsules can also help mask taste and odor and reduce bad aftertaste without the addition...

At Lonza, we’re driven by our purpose to enable a healthier world. It’s the ‘why’ behind everything we do and it’s the driving force behind our Launch with Lonza™ application lab services. From innovation to commercialization, our multi-disciplinary team brings more than 100 years of combined knowledge to ...

OceanCaps® capsules are a marine-based capsule well-matched to the needs of health conscious consumers. OceanCaps® capsules are ideally suited for marine supplements such as fish oil, DHA, EPA, salmon liver oil, shark cartilage and glucosamine and also offer the following benefits: • Made from high qua...

PCcaps® capsules are very small gelatin capsules that are ideal for oral delivery of the neat active in pre-clinical animal studies. They have been designed for performing pre-clinical trials such as pharmacokinetic, pharmacodynamic and animal safety studies. With PCcaps® capsules, there is no need to use ...

Vcaps® capsules are the first generation vegetarian capsules, meeting the needs of a wide variety of health-conscious consumers. With both KO and OU Kosher and Halal certification, and certified by the Vegetarian and Vegan Action Society, they are an appealing way to address the preferences of an important...

An immediate-release HPMC capsule, without gelling agents. Vcaps® Plus capsules offer excellent dissolution profile with pH-independent performance, standard or low-moisture content, great machinability and visual quality. Also available in TiO2 free and with food colorants.

Custom inner surface properties, customized moisture levels and more stringent microbial limits all designed to optimize inhalant end-product performance. Available in gelatin, gelatin-PEG, Capsugel® Vcaps® and Capsugel® Vcaps® Plus.

DBcaps® capsules were developed with a tamper-evident design to specifically address the clinical trial challenges of testing without bias. The wider diameter of opaque DBcaps® allows containment and blinding of large-diameter or uniquely-shaped tablets or other comparator products...

Oral solid dosage form with first of its kind enteric manufacturing technology. 
Discover a unique manufacturing process to build a bi-layer capsule to assist in enteric delivery. ​

An optimized tool for formulation development enabling compatibility studies before deciding on the final color for the commercial drug products. Available in gelatin and HPMC.​

In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

Dry-powder inhalation (DPI) technology offers a favorable drug development opportunity for respiratory or systemic drug delivery. Delivering a uniform dose in a portable, easy-to-use system, capsule-based DPI devices are a simple and cost-effective way to deliver inhalable medication. Capsugel® Zephyr™ is Lonza’s customizable dry-powder inhalation capsule portfolio that is optimized to provide superior performance and compatibility between the capsule/device and capsule/formulation.

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner. 

The Company Showcase profiles offer a library of free to access, downloadable content, including videos and webinars, reports, whitepapers and product brochures, from the Pharma suppliers and service providers you’d look to meet at our events.

A full suite of concept-to-market services to turn ideas into breakthrough products.

Discover the possibilities of TiO2-free white gelatin capsules without sacrificing quality and functionality.

The Capsugel®️ capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.

Explore Lonza new innovation center, dedicated to accelerating capsule development for oral and pulmonary drug delivery. Join us to discover how we foster collaboration with customers and co-innovation in a cutting-edge environment where science meets ingenuity. Learn how our expert team tackles complex formulation challenges, navigates global regulatory requirements, and supports your journey from concept to market. Experience how Lonza can partner with you to redefine the future of pharmaceutical excellence.